Wordt geladen...
Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
Estrogen receptor alpha (ERα)-positive breast cancers are frequently treated with tamoxifen, but resistance is common. It remains elusive how tamoxifen resistance occurs and predictive biomarkers for treatment outcome are needed. Because most biomarker discovery studies are performed using pre-treat...
Bewaard in:
Gepubliceerd in: | Oncotarget |
---|---|
Hoofdauteurs: | , , , , , , , , , , , , , , , , |
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
Impact Journals LLC
2016
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5085127/ https://ncbi.nlm.nih.gov/pubmed/27129152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8983 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|